Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy

NCT06932744 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Paroxysmal Nocturnal Haemoglobinuria (PNH)

Interventions

DRUG: MY008211A tablets
DRUG: Eculizumab Injection

Sponsor

Wuhan Createrna Science and Technology Co., Ltd